Pfizer, who once ruled the cardiac drug scene with Lipitor and Norvasc, is pulling out of heart medications to focus on more profitable areas like oncology and Alzheimer’s disease.
They got burned pretty badly with the HDL-raising drug torcetrapib, and their combo statin-hypertension medication Caduet is having anemic sales.
Profits obviously dictate where innovation should lie. The same thing happened to antibiotics where there hasn’t been a breakthrough drug in years.
Similar Posts:
- Do drug companies and the pharma industry deserve to be villains?
- Did the pharmaceutical industry pressure CBS to pull a television pilot?
- The risk of death from OxyContin and other narcotic drugs
KevinMD.com on Facebook
Comments on this entry are closed.